OC
MCID: OVR042
MIFTS: 83

Ovarian Cancer (OC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 58 12 77 54 26 76 38 30 56 6 44 15 3
Ovarian Carcinoma 54 26 13 56 17 74
Ovarian Neoplasms 56 6 45
Ovarian Neoplasm 12 17 74
Epithelial Ovarian Cancer 76 74
Ovarian Cancer, Somatic 58 13
Neoplasm of Ovary 30 6
Primary Malignant Neoplasm of Ovary 74
Malignant Neoplasm of the Ovary 26
Malignant Tumor of the Ovary 26
Malignant Neoplasm of Ovary 74
Malignant Tumour of Ovary 12
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 26
Tumor of the Ovary 12
Cancer, Ovarian 41
Ovary Neoplasm 12
Oc 76

Characteristics:

OMIM:

58
Inheritance:
somatic mutation


HPO:

33
ovarian cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:2394
OMIM 58 167000
KEGG 38 H00027
ICD9CM 36 183.0
MeSH 45 D010051
NCIt 51 C4984 C7431
SNOMED-CT 69 93934004
ICD10 34 C56
SNOMED-CT via HPO 70 254838004 263681008 60718004

Summaries for Ovarian Cancer

NIH Rare Diseases : 54 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and ovarian cancer 1, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are MicroRNAs in cancer and TGF-Beta Pathway. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and ovary, and related phenotypes are abnormality of metabolism/homeostasis and breast carcinoma

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Genetics Home Reference : 26 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

OMIM : 58 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

MedlinePlus : 44 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 Learn how to lower your risk and about the symptoms, risk factors, and treatment for ovarian cancer.

Novus Biologicals : 57 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

UniProtKB/Swiss-Prot : 76 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Wikipedia : 77 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 676)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 35.4 BRCA1 BRCA2 BRIP1 PALB2 PTEN
2 ovarian cancer 1 35.2 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
3 breast cancer 34.4 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
4 hereditary site-specific ovarian cancer syndrome 34.2 BRCA1 BRCA2
5 pancreatic cancer 34.0 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
6 lynch syndrome 33.5 BRAF BRCA1 BRCA2 CTNNB1 KRAS
7 ovarian clear cell carcinoma 33.5 KRAS PIK3CA PTEN
8 ovarian disease 33.3 AKT1 BRCA1 BRCA2 PTEN
9 ovary epithelial cancer 33.1 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
10 ovarian serous carcinoma 32.8 MIR200A MIR200C MIR214
11 colorectal cancer 32.3 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
12 endometrial cancer 32.2 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
13 adenocarcinoma 32.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
14 prostate cancer 32.1 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
15 lung cancer 32.0 AKT1 BRAF CDH1 ERBB2 KRAS MIR200A
16 carcinosarcoma 31.9 CTNNB1 ERBB2 KRAS PIK3CA PTEN
17 cervical cancer 31.7 AKT1 CDH1 CTNNB1 ERBB2 MIR214 PIK3CA
18 primary peritoneal carcinoma 31.6 BRCA1 BRCA2 ERBB2
19 endometrial adenocarcinoma 31.4 AKT1 CTNNB1 ERBB2 KRAS PTEN
20 lung cancer susceptibility 3 31.4 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
21 melanoma 31.4 BRAF MIR200A MIR200B MIR200C PTEN
22 squamous cell carcinoma 31.4 AKT1 BRAF CDH1 CTNNB1 ERBB2 PIK3CA
23 pancreas adenocarcinoma 31.3 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
24 bladder urothelial carcinoma 31.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
25 glioblastoma 31.2 AKT1 BRAF BRCA2 ERBB2 PIK3CA PTEN
26 testicular germ cell tumor 31.2 BRAF MIR200C PTEN
27 cholangiocarcinoma 31.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
28 squamous cell carcinoma, head and neck 31.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 MIR200A
29 transitional cell carcinoma 31.2 BRAF CDH1 ERBB2 PTEN
30 medulloblastoma 31.1 AKT1 BRCA2 CTNNB1 ERBB2 PIK3CA PTEN
31 fanconi anemia, complementation group a 31.1 BRCA1 BRCA2 BRIP1 PALB2
32 gastrointestinal stromal tumor 31.1 AKT1 BRAF KRAS PTEN
33 hepatocellular carcinoma 31.1 AKT1 CDH1 CTNNB1 KRAS MIR200A MIR200B
34 fallopian tube carcinoma 31.1 BRCA1 BRCA2 ERBB2
35 in situ carcinoma 31.1 BRCA1 CDH1 ERBB2
36 thyroid cancer 31.1 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
37 esophageal cancer 31.1 AKT1 CDH1 CTNNB1 ERBB2 KRAS PIK3CA
38 papillary carcinoma 31.1 BRAF CDH1 ERBB2
39 bilateral breast cancer 31.0 BRCA1 BRCA2 ERBB2 PALB2
40 cystadenocarcinoma 31.0 AKT1 ERBB2 PIK3CA
41 ductal carcinoma in situ 31.0 AKT1 BRCA1 BRCA2 CDH1 ERBB2
42 gallbladder cancer 31.0 AKT1 CDH1 ERBB2 KRAS PIK3CA
43 breast adenocarcinoma 30.9 AKT1 ERBB2 KRAS PIK3CA PTEN
44 li-fraumeni syndrome 30.9 BRCA1 BRCA2 PTEN
45 glioma 30.9 BRAF BRCA2 ERBB2 PIK3CA PTEN
46 sporadic breast cancer 30.9 BRCA1 BRCA2 ERBB2 PTEN
47 peutz-jeghers syndrome 30.9 BRCA2 CTNNB1 PTEN
48 ovarian serous cystadenocarcinoma 30.9 AKT1 BRAF ERBB2 PIK3CA
49 serous cystadenocarcinoma 30.8 AKT1 ERBB2 PIK3CA
50 uterine corpus serous adenocarcinoma 30.8 BRCA1 ERBB2 PIK3CA

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Human phenotypes related to Ovarian Cancer:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 33 HP:0001939
2 breast carcinoma 33 HP:0003002
3 dysgerminoma 33 HP:0100621
4 ovarian papillary adenocarcinoma 33 HP:0006774

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
dysgerminoma
ovarian papillary adenocarcinoma
breast cancer
ovarian cancer
serous ovarian cystadenocarcinoma

Laboratory Abnormalities:
frequent loss of heterozygosity at 6q24-q27

Clinical features from OMIM:

167000

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

27 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.51 CTNNB1 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.51 BRAF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.51 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.51 PIK3CA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.51 KRAS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.51 BRAF
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.51 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.51 AKT1 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.51 BRAF PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.51 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.51 AKT1 BRAF CTNNB1 KRAS PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.51 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.51 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.51 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.51 CTNNB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.51 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.51 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.51 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.51 BRAF
20 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.51 BRAF
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.51 AKT1 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.51 BRAF CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.51 CTNNB1 KRAS PIK3CA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.51 AKT1 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.51 KRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.51 CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.51 AKT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.51 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.51 CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.51 AKT1 CTNNB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.51 AKT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.51 KRAS
33 Decreased viability GR00055-A-2 10.35 BRAF KRAS
34 Decreased viability GR00106-A-0 10.35 KRAS
35 Decreased viability GR00221-A-1 10.35 CDH1 KRAS
36 Decreased viability GR00221-A-2 10.35 BRCA1 KRAS
37 Decreased viability GR00221-A-3 10.35 BRCA1
38 Decreased viability GR00221-A-4 10.35 BRAF
39 Decreased viability GR00301-A 10.35 BRAF BRCA1 CDH1 KRAS
40 Decreased viability GR00381-A-1 10.35 BRAF KRAS
41 Decreased viability GR00402-S-2 10.35 BRAF BRCA1 CDH1 KRAS
42 Decreased cell migration GR00055-A-1 9.8 AKT1 BRAF CTNNB1 KRAS PIK3CA
43 Increased cell migration GR00055-A-3 9.56 BRAF CTNNB1 KRAS PIK3CA
44 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 BRIP1
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 AKT1 BRCA1 BRCA2 PALB2 PRKN PTEN
46 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 AKT1 BRAF BRCA1 BRCA2 BRIP1 PALB2
47 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 BRIP1

MGI Mouse Phenotypes related to Ovarian Cancer:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
2 cardiovascular system MP:0005385 10.35 AKT1 BRAF BRCA1 CDH1 CTNNB1 ERBB2
3 behavior/neurological MP:0005386 10.32 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2
4 growth/size/body region MP:0005378 10.32 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
5 embryo MP:0005380 10.28 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
6 homeostasis/metabolism MP:0005376 10.27 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
7 endocrine/exocrine gland MP:0005379 10.26 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
8 integument MP:0010771 10.26 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
9 neoplasm MP:0002006 10.22 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
10 digestive/alimentary MP:0005381 10.15 BRAF BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
11 nervous system MP:0003631 10.15 AKT1 BRAF BRCA1 BRCA2 BRIP1 CTNNB1
12 muscle MP:0005369 10.09 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
13 limbs/digits/tail MP:0005371 10.06 BRAF BRCA1 BRCA2 CTNNB1 ERBB2 KRAS
14 normal MP:0002873 10.02 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
15 reproductive system MP:0005389 9.9 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
16 pigmentation MP:0001186 9.65 BRAF BRCA1 CTNNB1 KRAS PTEN
17 respiratory system MP:0005388 9.56 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
18 skeleton MP:0005390 9.32 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2

Drugs & Therapeutics for Ovarian Cancer

FDA approved drugs:

(show top 50) (show all 228)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Abraxane 19 50 PACLITAXEL Celgene October 2012
2
Abstral 19 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 19 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 19 50 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 19 50 EVEROLIMUS Novartis March 2009
6
Akynzeo 19 50 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Alimta 19 50 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
8
Aloxi 19 50 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
9
Anexsia 19 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
10
Anzemet 19 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
11
Aredia 19 50 PAMIDRONATE DISODIUM Chiron August 1996
12
Arimidex 19 50 ANASTROZOLE AstraZeneca January 1996
13
Aromasin Tablets 19 50 EXEMESTANE Pharmacia & Upjohn October 21. 1999
14
Arranon 19 50 NELARABINE GlaxoSmithKline October 2005
15
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
16
Avastin 19 50 BEVACIZUMAB Genentech July 2009
17
Beleodaq 19 50 BELINOSTAT Spectrum Pharmaceuticals July 2014
18
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
19
Blincyto 19 50 BLINATUMOMAB Amgen December 2014
20
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
21
Bromfenac 19 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
22
Busulfex 19 50 BUSULFAN Orphan Medical February 1999
23
Campath 19 50 ALEMTUZUMAB Berlex Laboratories May 2001
24
CEA-Scan 19 Immunomedics April 1996
25
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
26
Clolar 19 50 CLOFARABINE Genzyme December, 2004
27
Cometriq 19 50 CABOZANTINIB S-MALATE Exelixis November 2012
28
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
29
Degarelix 19 50 degarelix Ferring Pharmaceuticals December of 2008
30
Doxil 19 50 DOXORUBICIN HYDROCHLORIDE Alza June 1999
31
Elitek 19 50 RASBURICASE sanofi-aventis October 2009
32
Ellence 19 50 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
33
Elliotts B Solution 19 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
34
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
35
Emend 19 50 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
36
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
37
Erivedge 19 50 VISMODEGIB Genentech January 2012
38
Erwinaze 19 50 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
39
Ethyol 19 AMIFOSTINE Alza December 8, 1995
40
Eulexin 19 FLUTAMIDE Schering-Plough June 1996
41
Evista 19 50 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
42
Farydak 19 50 PANOBINOSTAT LACTATE Novartis February 2015
43
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
44
Femara 19 50 LETROZOLE Novartis January 2001
45
Feridex I.V. 19 FERUMOXIDES Advanced Magnetics February 1996
46
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
47
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
48
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
49
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
50
Gemzar 19 50 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 714)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
4
Peppermint Approved Phase 4
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Ferrous fumarate Approved Phase 4,Early Phase 1,Not Applicable 141-01-5
9
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 114977-28-5 148124
10
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
11
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
12
Niraparib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
15
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 151165 6918365
16
Iron Approved, Experimental Phase 4,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
17
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
20
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
21 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Coagulants Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2551)
# Name Status NCT ID Phase Drugs
1 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
4 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
5 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
6 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
7 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
8 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
9 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
10 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
11 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
12 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
13 Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
14 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
15 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
16 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
17 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
18 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
19 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
20 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
21 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
22 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
23 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
24 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
25 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
26 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
27 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
28 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
29 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
30 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
31 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
32 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
33 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
34 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
35 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
36 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
37 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
38 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
39 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
40 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
41 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
42 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
43 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
44 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
45 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
46 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
47 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
48 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed NCT02421588 Phase 3 Lurbinectedin (PM01183);Pegylated liposomal doxorubicin (PLD);Topotecan
49 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
50 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed NCT00113607 Phase 3 Trabectedin;DOXIL;Dexamethasone

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 30 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 30

Anatomical Context for Ovarian Cancer

MalaCards organs/tissues related to Ovarian Cancer:

42
Breast, Testes, Ovary, Lung, T Cells, Endothelial, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

20
The Ovary

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 14738)
# Title Authors Year
1
Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. ( 30766885 )
2019
2
Intolerance of uncertainty, social support, and loneliness in relation to anxiety and depressive symptoms among women diagnosed with ovarian cancer. ( 30614141 )
2019
3
Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). ( 30616086 )
2019
4
Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand. ( 30789886 )
2019
5
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. ( 30725383 )
2019
6
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients ( 30678441 )
2019
7
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. ( 30655615 )
2019
8
Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. ( 29790947 )
2019
9
Identification of Key Candidate Genes and Pathways for Relationship between Ovarian Cancer and Diabetes Mellitus Using Bioinformatical Analysis ( 30678426 )
2019
10
Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics. ( 30913953 )
2019
11
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer. ( 30657901 )
2019
12
Endometriosis-associated ovarian cancer: What have we learned so far? ( 30776361 )
2019
13
Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. ( 30387804 )
2019
14
LINK-A Long Non-Coding RNA (lncRNA) Participates in Metastasis of Ovarian Carcinoma and Upregulates Hypoxia-Inducible Factor 1 (HIF1α). ( 30912527 )
2019
15
Contribution of FPR and TLR9 to hypoxia-induced chemoresistance of ovarian cancer cells. ( 30643427 )
2019
16
Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. ( 30536571 )
2019
17
Hydropic leiomyoma presenting as a rare condition of pseudo-Meigs syndrome: literature review and a case of a pseudo-Meigs syndrome mimicking ovarian carcinoma with elevated CA125. ( 30635302 )
2019
18
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations. ( 30414230 )
2019
19
Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. ( 30623411 )
2019
20
Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. ( 30695780 )
2019
21
Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer. ( 30675307 )
2019
22
Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer. ( 30790382 )
2019
23
Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years. ( 30905435 )
2019
24
Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study. ( 30905436 )
2019
25
MicroRNA-34 suppresses proliferation of human ovarian cancer cells by triggering autophagy and apoptosis and inhibits cell invasion by targeting Notch 1. ( 30905732 )
2019
26
Epithelial ovarian cancer: feasibility of image-guided intratumoral radiofrequency hyperthermia-enhanced direct gene therapy. ( 30906635 )
2019
27
Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. ( 30907434 )
2019
28
Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo. ( 30909184 )
2019
29
Therapeutic Targeting of Collective Invasion in Ovarian Cancer. ( 30909510 )
2019
30
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. ( 30909618 )
2019
31
Erratum to: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. ( 30909989 )
2019
32
Epithelial ovarian cancer. ( 30910306 )
2019
33
Chromatin target of protein arginine methyltransferase (CHTOP) regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer. ( 30910850 )
2019
34
Complete surgical resection of isolated recurrent high-grade epithelial ovarian cancer in highly selected patients without chemotherapy is associated with an excellent outcome. ( 30911592 )
2019
35
ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. ( 30913193 )
2019
36
ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. ( 30913199 )
2019
37
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects. ( 30914056 )
2019
38
Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/β-Catenin Signaling. ( 30915350 )
2019
39
Serum selenium and pancreatic cancer: a prospective study in the Prostate, Lung, Colorectal and Ovarian Cancer Trial cohort. ( 30915619 )
2019
40
MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1. ( 30915736 )
2019
41
Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer. ( 30916767 )
2019
42
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience. ( 30843318 )
2019
43
Nectin-2 in Ovarian Cancer: how is it expressed and what might be its functional role? ( 30843637 )
2019
44
Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth. ( 30845699 )
2019
45
Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. ( 30845964 )
2019
46
Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision. ( 30846223 )
2019
47
Interactions of ficolin-3 with ovarian cancer cells. ( 30846332 )
2019
48
LncRNA SNHG20 predicts a poor prognosis and promotes cell progression in epithelial ovarian cancer. ( 30846486 )
2019
49
Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? ( 30847169 )
2019
50
Confusion following Treatment of Ovarian Cancer. ( 30849385 )
2019

Variations for Ovarian Cancer

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer:

76
# Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691
7 PIK3CA p.His1047Arg VAR_026192 rs121913279

ClinVar genetic disease variations for Ovarian Cancer:

6 (show top 50) (show all 577)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSH2 NM_000251.2(MSH2): c.1927G> A (p.Glu643Lys) single nucleotide variant Uncertain significance rs374840361 GRCh37 Chromosome 2, 47702331: 47702331
2 MSH2 NM_000251.2(MSH2): c.1927G> A (p.Glu643Lys) single nucleotide variant Uncertain significance rs374840361 GRCh38 Chromosome 2, 47475192: 47475192
3 MSH2 NM_000251.2(MSH2): c.2203A> G (p.Ile735Val) single nucleotide variant Uncertain significance rs2229061 GRCh37 Chromosome 2, 47703703: 47703703
4 MSH2 NM_000251.2(MSH2): c.2203A> G (p.Ile735Val) single nucleotide variant Uncertain significance rs2229061 GRCh38 Chromosome 2, 47476564: 47476564
5 ABCB1 NM_000927.4(ABCB1): c.2677T> A (p.Ser893Thr) single nucleotide variant Benign rs2032582 GRCh37 Chromosome 7, 87160618: 87160618
6 ABCB1 NM_000927.4(ABCB1): c.2677T> A (p.Ser893Thr) single nucleotide variant Benign rs2032582 GRCh38 Chromosome 7, 87531302: 87531302
7 BRIP1 NM_032043.2(BRIP1): c.3559G> A (p.Ala1187Thr) single nucleotide variant Uncertain significance rs367610893 GRCh38 Chromosome 17, 61683487: 61683487
8 BRIP1 NM_032043.2(BRIP1): c.3559G> A (p.Ala1187Thr) single nucleotide variant Uncertain significance rs367610893 GRCh37 Chromosome 17, 59760848: 59760848
9 BRIP1 NM_032043.2(BRIP1): c.3196delT (p.Ser1066Hisfs) deletion Conflicting interpretations of pathogenicity rs730881645 GRCh38 Chromosome 17, 61683850: 61683850
10 BRIP1 NM_032043.2(BRIP1): c.3196delT (p.Ser1066Hisfs) deletion Conflicting interpretations of pathogenicity rs730881645 GRCh37 Chromosome 17, 59761211: 59761211
11 BRIP1 NM_032043.2(BRIP1): c.2390A> G (p.Lys797Arg) single nucleotide variant Uncertain significance rs730881622 GRCh38 Chromosome 17, 61716053: 61716053
12 BRIP1 NM_032043.2(BRIP1): c.2390A> G (p.Lys797Arg) single nucleotide variant Uncertain significance rs730881622 GRCh37 Chromosome 17, 59793414: 59793414
13 BRIP1 NM_032043.2(BRIP1): c.2255_2256delAA (p.Lys752Argfs) deletion Pathogenic rs730881649 GRCh38 Chromosome 17, 61744433: 61744434
14 BRIP1 NM_032043.2(BRIP1): c.2255_2256delAA (p.Lys752Argfs) deletion Pathogenic rs730881649 GRCh37 Chromosome 17, 59821794: 59821795
15 BRIP1 NM_032043.2(BRIP1): c.2232C> T (p.Asp744=) single nucleotide variant Benign/Likely benign rs374362388 GRCh38 Chromosome 17, 61744457: 61744457
16 BRIP1 NM_032043.2(BRIP1): c.2232C> T (p.Asp744=) single nucleotide variant Benign/Likely benign rs374362388 GRCh37 Chromosome 17, 59821818: 59821818
17 BRIP1 NM_032043.2(BRIP1): c.2097+8A> C single nucleotide variant Benign/Likely benign rs730881642 GRCh38 Chromosome 17, 61776393: 61776393
18 BRIP1 NM_032043.2(BRIP1): c.2097+8A> C single nucleotide variant Benign/Likely benign rs730881642 GRCh37 Chromosome 17, 59853754: 59853754
19 BRIP1 NM_032043.2(BRIP1): c.1935+11_1935+13delGTT deletion Conflicting interpretations of pathogenicity rs730881641 GRCh38 Chromosome 17, 61780248: 61780250
20 BRIP1 NM_032043.2(BRIP1): c.1935+11_1935+13delGTT deletion Conflicting interpretations of pathogenicity rs730881641 GRCh37 Chromosome 17, 59857609: 59857611
21 BRIP1 NM_032043.2(BRIP1): c.1684A> G (p.Ile562Val) single nucleotide variant Uncertain significance rs45533636 GRCh38 Chromosome 17, 61780950: 61780950
22 BRIP1 NM_032043.2(BRIP1): c.1684A> G (p.Ile562Val) single nucleotide variant Uncertain significance rs45533636 GRCh37 Chromosome 17, 59858311: 59858311
23 BRIP1 NM_032043.2(BRIP1): c.852C> T (p.Val284=) single nucleotide variant Benign/Likely benign rs144940449 GRCh38 Chromosome 17, 61808533: 61808533
24 BRIP1 NM_032043.2(BRIP1): c.852C> T (p.Val284=) single nucleotide variant Benign/Likely benign rs144940449 GRCh37 Chromosome 17, 59885894: 59885894
25 BRIP1 NM_032043.2(BRIP1): c.655T> C (p.Cys219Arg) single nucleotide variant Uncertain significance rs730881630 GRCh38 Chromosome 17, 61808730: 61808730
26 BRIP1 NM_032043.2(BRIP1): c.655T> C (p.Cys219Arg) single nucleotide variant Uncertain significance rs730881630 GRCh37 Chromosome 17, 59886091: 59886091
27 BRIP1 NM_032043.2(BRIP1): c.394A> T (p.Thr132Ser) single nucleotide variant Uncertain significance rs730881623 GRCh38 Chromosome 17, 61849242: 61849242
28 BRIP1 NM_032043.2(BRIP1): c.394A> T (p.Thr132Ser) single nucleotide variant Uncertain significance rs730881623 GRCh37 Chromosome 17, 59926603: 59926603
29 BRIP1 NM_032043.2(BRIP1): c.380-17dupT duplication Benign/Likely benign rs545021924 GRCh38 Chromosome 17, 61849273: 61849273
30 BRIP1 NM_032043.2(BRIP1): c.380-17dupT duplication Benign/Likely benign rs545021924 GRCh37 Chromosome 17, 59926634: 59926634
31 BRIP1 NM_032043.2(BRIP1): c.370A> G (p.Thr124Ala) single nucleotide variant Uncertain significance rs45617634 GRCh38 Chromosome 17, 61857067: 61857067
32 BRIP1 NM_032043.2(BRIP1): c.370A> G (p.Thr124Ala) single nucleotide variant Uncertain significance rs45617634 GRCh37 Chromosome 17, 59934428: 59934428
33 BRIP1 NM_032043.2(BRIP1): c.258_269delTTGTTGTGCATG (p.Cys87_Cys90del) deletion Uncertain significance rs730881648 GRCh38 Chromosome 17, 61857168: 61857179
34 BRIP1 NM_032043.2(BRIP1): c.258_269delTTGTTGTGCATG (p.Cys87_Cys90del) deletion Uncertain significance rs730881648 GRCh37 Chromosome 17, 59934529: 59934540
35 BRIP1 NM_032043.2(BRIP1): c.195A> G (p.Gln65=) single nucleotide variant Benign/Likely benign rs141436143 GRCh38 Chromosome 17, 61859806: 61859806
36 BRIP1 NM_032043.2(BRIP1): c.195A> G (p.Gln65=) single nucleotide variant Benign/Likely benign rs141436143 GRCh37 Chromosome 17, 59937167: 59937167
37 BRIP1 NM_032043.2(BRIP1): c.93+15G> A single nucleotide variant Conflicting interpretations of pathogenicity rs113052745 GRCh38 Chromosome 17, 61861432: 61861432
38 BRIP1 NM_032043.2(BRIP1): c.93+15G> A single nucleotide variant Conflicting interpretations of pathogenicity rs113052745 GRCh37 Chromosome 17, 59938793: 59938793
39 BRIP1 NM_032043.2(BRIP1): c.3651G> A (p.Trp1217Ter) single nucleotide variant Uncertain significance rs542698396 GRCh37 Chromosome 17, 59760756: 59760756
40 BRIP1 NM_032043.2(BRIP1): c.3651G> A (p.Trp1217Ter) single nucleotide variant Uncertain significance rs542698396 GRCh38 Chromosome 17, 61683395: 61683395
41 BRIP1 NM_032043.2(BRIP1): c.3571A> G (p.Ile1191Val) single nucleotide variant Uncertain significance rs761405340 GRCh37 Chromosome 17, 59760836: 59760836
42 BRIP1 NM_032043.2(BRIP1): c.3571A> G (p.Ile1191Val) single nucleotide variant Uncertain significance rs761405340 GRCh38 Chromosome 17, 61683475: 61683475
43 BRIP1 NM_032043.2(BRIP1): c.3411T> C (p.Tyr1137=) single nucleotide variant Benign/Likely benign rs4986763 GRCh38 Chromosome 17, 61683635: 61683635
44 BRIP1 NM_032043.2(BRIP1): c.3411T> C (p.Tyr1137=) single nucleotide variant Benign/Likely benign rs4986763 GRCh37 Chromosome 17, 59760996: 59760996
45 BRIP1 NM_032043.2(BRIP1): c.3099T> C (p.Pro1033=) single nucleotide variant Conflicting interpretations of pathogenicity rs202228407 GRCh38 Chromosome 17, 61683947: 61683947
46 BRIP1 NM_032043.2(BRIP1): c.3099T> C (p.Pro1033=) single nucleotide variant Conflicting interpretations of pathogenicity rs202228407 GRCh37 Chromosome 17, 59761308: 59761308
47 BRIP1 NM_032043.2(BRIP1): c.3096T> G (p.Ser1032Arg) single nucleotide variant Uncertain significance rs763162379 GRCh37 Chromosome 17, 59761311: 59761311
48 BRIP1 NM_032043.2(BRIP1): c.3096T> G (p.Ser1032Arg) single nucleotide variant Uncertain significance rs763162379 GRCh38 Chromosome 17, 61683950: 61683950
49 BRIP1 NM_032043.2(BRIP1): c.3050C> T (p.Pro1017Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs747907706 GRCh37 Chromosome 17, 59761357: 59761357
50 BRIP1 NM_032043.2(BRIP1): c.3050C> T (p.Pro1017Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs747907706 GRCh38 Chromosome 17, 61683996: 61683996

Copy number variations for Ovarian Cancer from CNVD:

7 (show top 50) (show all 8010)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion APITD1 Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion C1orf126 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion C1orf144 Ovarian cancer
33 13445 1 1 23549970 Deletion C1orf151 Ovarian cancer
34 13446 1 1 23549970 Deletion C1orf158 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion C1orf170 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion C1orf187 Ovarian cancer
39 13451 1 1 23549970 Deletion C1orf200 Ovarian cancer
40 13452 1 1 23549970 Deletion C1orf64 Ovarian cancer
41 13453 1 1 23549970 Deletion C1orf70 Ovarian cancer
42 13454 1 1 23549970 Deletion C1orf86 Ovarian cancer
43 13455 1 1 23549970 Deletion C1orf89 Ovarian cancer
44 13456 1 1 23549970 Deletion C1orf93 Ovarian cancer
45 13457 1 1 23549970 Deletion CA6 Ovarian cancer
46 13458 1 1 23549970 Deletion CALML6 Ovarian cancer
47 13459 1 1 23549970 Deletion CAMK2N1 Ovarian cancer
48 13460 1 1 23549970 Deletion CAMTA1 Ovarian cancer
49 13461 1 1 23549970 Deletion CAPZB Ovarian cancer
50 13462 1 1 23549970 Deletion CASP9 Ovarian cancer

Expression for Ovarian Cancer

Search GEO for disease gene expression data for Ovarian Cancer.

Pathways for Ovarian Cancer

Pathways related to Ovarian Cancer according to KEGG:

38
# Name Kegg Source Accession
1 MicroRNAs in cancer hsa05206

Pathways related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 AKT1 BRAF BRCA1